[Advances in Molecular Subtyping, Characteristics and Therapeutic Strategies of  Small Cell Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2023 May 15

PMID 37183645

Authors

Yang Wu

Jing Zhao

Mengzhao Wang

Affiliations

Soon will be listed here.

Abstract

Small cell lung cancer (SCLC) is a malignant tumor with remarkable proliferative and invasive ability, which has very poor clinical prognosis due to lack of effective treatments. In recent years, researches on cells, animal models and tumor samples have promoted the identification of molecular subtypes of SCLC, discovered unique biological and clinical characteristics, and proposed potential specific therapeutic targets for different subtypes. This will encourage the development of more accurate therapeutic strategies towards SCLC, with a view to improving the prognosis of the patients. This article will review the current SCLC molecular subtypes, focus on the clinical characteristics and therapeutic strategies of different SCLC subtypes, and propose reasonable suggestions for the future treatment of SCLC. .

References

Osborne J, Larsen J, Shields M, Gonzales J, Shames D, Sato M . NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proc Natl Acad Sci U S A. 2013; 110(16):6524-9. PMC: 3631659. DOI: 10.1073/pnas.1303932110. View

Pietanza M, Waqar S, Krug L, Dowlati A, Hann C, Chiappori A . Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(23):2386-2394. PMC: 6085179. DOI: 10.1200/JCO.2018.77.7672. View

Inno A, Stagno A, Gori S . Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?. Transl Lung Cancer Res. 2019; 7(Suppl 4):S341-S345. PMC: 6328697. DOI: 10.21037/tlcr.2018.11.06. View

Miyata T, Maeda T, Lee J . NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. Genes Dev. 1999; 13(13):1647-52. PMC: 316850. DOI: 10.1101/gad.13.13.1647. View

Schwendenwein A, Megyesfalvi Z, Barany N, Valko Z, Bugyik E, Lang C . Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics. 2021; 20:470-483. PMC: 7917449. DOI: 10.1016/j.omto.2021.02.004. View

McColl K, Wildey G, Sakre N, Lipka M, Behtaj M, Kresak A . Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget. 2017; 8(43):73745-73756. PMC: 5650296. DOI: 10.18632/oncotarget.20572. View

Masso-Valles D, Beaulieu M, Soucek L . MYC, MYCL, and MYCN as therapeutic targets in lung cancer. Expert Opin Ther Targets. 2020; 24(2):101-114. DOI: 10.1080/14728222.2020.1723548. View

Rudin C, Pietanza M, Bauer T, Ready N, Morgensztern D, Glisson B . Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2016; 18(1):42-51. PMC: 5481162. DOI: 10.1016/S1470-2045(16)30565-4. View

Horie M, Saito A, Ohshima M, Suzuki H, Nagase T . YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. Cancer Sci. 2016; 107(12):1755-1766. PMC: 5198951. DOI: 10.1111/cas.13078. View

10.

Shibata M, Ham K, Hoque M . A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018; 143(9):2133-2144. PMC: 6540999. DOI: 10.1002/ijc.31561. View

11.

Hoffman S, Friedlander D, Chuong C, Grumet M, Edelman G . Differential contributions of Ng-CAM and N-CAM to cell adhesion in different neural regions. J Cell Biol. 1986; 103(1):145-58. PMC: 2113806. DOI: 10.1083/jcb.103.1.145. View

12.

Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O . Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021; 39(11):1479-1496.e18. PMC: 8628860. DOI: 10.1016/j.ccell.2021.09.008. View

13.

Jia D, Augert A, Kim D, Eastwood E, Wu N, Ibrahim A . Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov. 2018; 8(11):1422-1437. PMC: 6294438. DOI: 10.1158/2159-8290.CD-18-0385. View

14.

Wang X, Guo Y, Liu L, Wei J, Zhang J, Xie T . YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. Lung Cancer. 2021; 160:166-174. DOI: 10.1016/j.lungcan.2021.06.026. View

15.

Yamashita J, Ohmoto M, Yamaguchi T, Matsumoto I, Hirota J . Skn-1a/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice. PLoS One. 2017; 12(12):e0189340. PMC: 5720759. DOI: 10.1371/journal.pone.0189340. View

16.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

17.

Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View

18.

Mollaoglu G, Guthrie M, Bohm S, Bragelmann J, Can I, Ballieu P . MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell. 2017; 31(2):270-285. PMC: 5310991. DOI: 10.1016/j.ccell.2016.12.005. View

19.

Borges M, Linnoila R, van de Velde H, Chen H, Nelkin B, MABRY M . An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997; 386(6627):852-5. DOI: 10.1038/386852a0. View

20.

Tian Y, Li Q, Yang Z, Zhang S, Xu J, Wang Z . Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Signal Transduct Target Ther. 2022; 7(1):346. PMC: 9532437. DOI: 10.1038/s41392-022-01150-4. View

[Advances in Molecular Subtyping, Characteristics and Therapeutic Strategies of Small Cell Lung Cancer]

[Advances in Molecular Subtyping, Characteristics and Therapeutic Strategies of  Small Cell Lung Cancer]